Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136404 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT05136404: Completed Phase 1 study, sponsored by Loxo Oncology.
NCT05136404 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05136404, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 59 days including the 28 days of screening period.
Primary Outcome
PK: Cmax of Selpercatinib
Interventions
- DRUG Selpercatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-12-03 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 1 |
What the finished NCT05136404 record still lists
NCT05136404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 1 intervention - of which Selpercatinib is the first listed.
NCT05136404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05136404 about?
NCT05136404 is a clinical study titled "A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants". The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected ...
What is the current status of trial NCT05136404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-12-03. Estimated completion is 2022-03-14.
What interventions are being tested in trial NCT05136404?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT05136404?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05136404's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI